Quidel Licenses U of Colorado's MChip for Point-of-Care Flu Testing | GenomeWeb
NEW YORK (GenomeWeb News) – Diagnostic test provider Quidel said last week that it has signed an exclusive, worldwide license for the MChip microarray-based influenza detection technology developed by scientists at the University of Colorado and the US Centers for Disease Control and Prevention.
 
The company said it plans to develop and market molecular-based diagnostic tests based on the MChip for use in pandemic surveillance, as a tool for clinical labs, and for point-of-care use in physicians’ offices.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.